# US 8,771,700 B2 · Interferon antagonists, antibodies thereto and associated methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,700 B2
- Document ID: US8771700B2
- Status: Granted
- Kind: B2
- Application number: 12/310,432
- Filed: 2007-08-23
- Published: 2011-02-03
- Granted: 2014-07-08
- Earliest claimed: 2006-08-23
- Assignees: Rutgers, The State University of New Jersey
- Applicants: Sergei V. Kotenko; Geoffrey L. Smith
- Inventors: Sergei V. Kotenko; Geoffrey L. Smith
- Web page: https://patentgrep.com/patent/US8771700B2

## CPC

- C07K 14/005: from viruses
- A61K 38/162: {from virus}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/081: DNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2710/24033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.

## Claims

### Claim 1

A pharmaceutical composition comprising an isolated viral polypeptide of SEQ ID NO:1 having interferon (IFN) I and IFN III antagonist activity; and at least one of a pharmaceutically acceptable carrier, excipient, or adjuvant.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the polypeptide comprises a fusion protein.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the fusion protein comprises a polypeptide of SEQ ID NO:1 and a polypeptide of SEQ ID NO:5.

### Claim 4 (depends on 1)

A method for inhibiting the activity of an interferon comprising administering to a subject in need thereof the pharmaceutical composition of claim 1 so that the activity of an interferon is inhibited.

### Claim 5 (depends on 4)

The method of claim 4, wherein the interferon is at least one of a type I interferon, a type III interferon or a combination of both.

### Claim 6 (depends on 4)

The method of claim 4, wherein the subject has symptoms associated with an immunological condition.

### Claim 7 (depends on 6)

The method of claim 6, wherein the immunological condition is selected from the group of an autoimmune disease, systemic lupus erythematosus (SLE), acute allograft rejection, septic shock, and viral infection.